🚨 NEST is a big deal, and now fully published. 24 patients with localized CRC. BOT + BAL (CTLA4 + PD1) before surgery. 60% with major responses. We’ve been inching toward neoadjuvant therapy in colon cancer for years. FOxTROT tried it with chemotherapy and showed there was something there. NICHE then showed us that neoadjuvant immunotherapy can be wildly effective in dMMR/MSI-H colon cancer (I'm still pushing to rename this to Chalabi's disease). The real question has always been: can we make this work in pMMR/MSS disease? NEST says yes. Among the 22 pMMR tumors: 🔥 41% major pathologic response 🔥 32% pCR 🔥 59% had ≥50% tumor regression And no treatment-related delays to surgery. Chalabi's tumors (dMMR)? 100% MPR. It’s only a phase II, but a 32% pCR rate in pMMR colon cancer with immunotherapy is kind of insane. NEST is telling us MSS is be coming through the IO door next. And now we have ROBBIN (the phase III) coming. Get ready. Neoadjuvant therapy is going to become a much bigger part of how we treat colon cancer. This is where CRC is going. 🧬🔥 @OncoAlert @oncodaily @Onco_Nexus @TheGutOncLab